Home
Stocks
Marksans Pharma Ltd

Marksans Pharma Ltd share Price

NSE
BSE

Sep 26, 2023 03:57 PM

Marksans Pharma Ltd

SECTOR : Pharmaceuticals | BSE :524404 | NSE : MARKSANS

1D
1W
1M
3M
1Y
5Y
MAX

BUY SELL SEP

Company details

Day Low

Day High

103.75

106.50

52W Low

52W High

45.40

122.50

6M Return 50.32%

1Y Return 121.63%

Mkt Cap.(Cr) 4,805.80

Volume 1,140,374

Div Yield 0.47%

OI

-

OI Chg %

-

Volume 1,140,374

Quick Results Snapshot
SWOT Analysis
Financials
Comparison
Information
FAQs

Marksans Pharma Ltd: 106.05
0.25 (0.24 %)

NSE

Quick Results Snapshot

Marksans Pharma Ltd.

Q1FY24 Quarterly Result Announced for Marksans Pharma Ltd.

Pharmaceuticals company Marksans Pharma announced Q1FY24 results:

Operating revenue was Rs 500.0 crore, up by 15.3% YoY driven by market share gains in the existing products and markets
- US business grew by 11.2% YoY
- UK and Europe grew by 24.8% YoY
Gross profit was Rs 257.3 crore, up by 17.5% YoY with a Gross margin of 51.5%.
EBITDA was Rs 102.0 crore, grew by 39.9% with an EBITDA margin of 20.4%
EPS grew by 3.8% YoY to Rs 1.52
RoW business reported Rs 22.2 crore in Q1FY24
In Q1FY24, the capex incurred was Rs 81.5 crore Capex investment is in-line with our plan for scaling the acquired manufacturing unit from Teva Pharma in Goa
Cash Balance at the end of June 30, 2023 is at Rs 636 crore in Q1FY24
In Q1FY24, Cash from Operations is at Rs 49.8 crore

Result PDF

View Other Company Results

Marksans Pharma Ltd shares SWOT Analysis

EMA SMA

Delivery and volume

FINANCIALS

Sales

Operating Profit

Profit after Tax

DISCOVER MORE

Equity

Reserves and Surplus

Debt

DISCOVER MORE

Sales

Operating Profit

Profit after Tax

DISCOVER MORE

PE

Debt/Equity

P BV

DISCOVER MORE

Marksans Pharma Ltd Stocks COMPARISION

DISCOVER MORE

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 1,745.17 Cr FV: 1.00

Period	MF Net Purchase / (sold)	FII Net
LAST 1M	19,065.79	-9,437.36
LAST 3M	48,885.55	-453.72
LAST 6M	53,246.77	148,781.31
LAST 12M	137,184.48	160,910.46

ANNOUNCEMENT
CORPORATE ACTION

No Data Found

Date	Action Type	Ratio
Jun 07, 2023	Dividend	50
Aug 19, 2022	Dividend	25
Sep 15, 2021	Dividend	25

DISCOVER MORE

Marksans Pharma Ltd Information

Stock PE (TTM)
17.45

Promoter Holding
43.85%

Book Value
38.5106

ROCE
21.77%

ROE
18%

Description

Marksans Pharma Limited is a pharmaceutical company and has a market capitalization of Rs. 2,916 crores as of 18th August 2021. The company started on 16th April 1992. The company has reported a total quarterly income of Rs.354.84 crores at the end of June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 524404 and scrip code MARKSANS. As of 18th August 2021, Marksans Pharma’s shares were trading at Rs. 71.25.

The corporate is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company’s research and development centres are in Verna Goa and Navi Mumbai, respectively. With three manufacturing facilities in India, UK, and therefore the US, Marksans has established an authoritative position in regulated markets in India and abroad. The company currently has approximately 1200 employees globally with more than 500 registered products. It also has 50+ experienced scientists in the R& D facility. The promoter holding stood at 48.25% in June 2021 and has remained constant over the last 15 months. Promoters have zero pledged holdings.

In June 2021, the company reported total revenue of Rs. 354.84 crores as compared to Rs. 336.21 crores during the quarter ended March 2021. It had posted net profit / (loss) of Rs. 62.60 crores for the period ended June 2021 as compared to net profit / (loss) of Rs.79.49 crores for the period ended 31st March 2021. The company’s EPS was at Rs.1.51 for the period ended 30th June '2021, as against Rs.1.93 for the period ended 31st March '2021. On a year-on-year basis, the total income of the company has increased 7.10% from Rs. 331.33 crores to Rs. 354.84 crores with the net profit increasing 26.82% from Rs. 49.36 crores to Rs. 62.60 crores and with EPS increasing 25.83% to Rs. 1.51 as against Rs. 1.2 in June 2020. Over the last 5 years, the company’s market share has increased from 0.49% to 0.54%. Marksans Pharma’s shares closed at Rs. 71.25 (NSE) as of 18th August 2021 and has given a return of 30.38% over the last 12 months.

Marksans Pharma Limited is a pharmaceutical company and has a market capitalization of Rs. 2,916 crores as of 18th August 2021. The company started on 16th April 1992. The company has reported a total quarterly income of Rs.354.84 crores at the end of June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 524404 and scrip code MARKSANS. As of 18th August 2021, Marksans Pharma’s shares were trading at Rs. 71.25.

The corporate is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company’s research and development centres are in Verna Goa and Navi Mumbai, respectively. With three manufacturing facilities in India, UK, and therefore the US, Marksans has established an authoritative position in regulated markets in India and abroad. The company currently has approximately 1200 employees globally with more than 500 registered products. It also has 50+ experienced scientists in the R& D facility. The promoter holding stood at 48.25% in June 2021 and has remained constant over the last 15 months. Promoters have zero pledged holdings.

In June 2021, the company reported total revenue of Rs. 354.84 crores as compared to Rs. 336.21 crores during the quarter ended March 2021. It had posted net profit / (loss) of Rs. 62.60 crores for the period ended June 2021 as compared to net profit / (loss) of Rs.79.49 crores for the period ended 31st March 2021. The company’s EPS was at Rs.1.51 for the period ended 30th June '2021, as against Rs.1.93 for the period ended 31st March '2021. On a year-on-year basis, the total income of the company has increased 7.10% from Rs. 331.33 crores to Rs. 354.84 crores with the net profit increasing 26.82% from Rs. 49.36 crores to Rs. 62.60 crores and with EPS increasing 25.83% to Rs. 1.51 as against Rs. 1.2 in June 2020. Over the last 5 years, the company’s market share has increased from 0.49% to 0.54%. Marksans Pharma’s shares closed at Rs. 71.25 (NSE) as of 18th August 2021 and has given a return of 30.38% over the last 12 months.

Registered Address

11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053

Tel	:	91-22-40012000
Email	:	companysecretary:marksanspharma.com
Website	:	http://www.marksanspharma.com

Registrar

Bigshare Services Pvt Ltd

AGM Date (Month)	:	Aug
Face Value Equity Shares	:	1
Market Lot Equity Shares	:	1
BSE Code	:	524404
NSE Code	:	MARKSANS
Book Closure Date (Month)	:
BSE Group	:	A
ISIN	:	INE750C01026

FAQ’s on Marksans Pharma Ltd Shares

How can I buy Marksans Pharma Ltd share?

You can buy Marksans Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Marksans Pharma Ltd Share.

What is the share price of Marksans Pharma Ltd share?

Company share prices and volatile and keep changing according to the market conditions. As of Sep 26, 2023 03:57 PM the closing price of Marksans Pharma Ltd was ₹ 106.05.

What is the market cap of Marksans Pharma Ltd?

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 26, 2023 03:57 PM, the market cap of Marksans Pharma Ltd stood at ₹ 4,805.80.